As reported by DrugStoreNews.com, there has been a lot of discussion in the biotechnology world over the appropriate names of follow-on biologics. “Follow-on biologics,” also known as “biosimilars,” are “biologic medical products whose active drug substance is made by a living organism or derived from a living organism by means of recombinant DNA
Big pharma takes pages out of asbestos playbook.
Can you trust your advocacy organization to disclose their ties to big pharma? Looks like there’s only a one-in-four chance that you can.
The study analyzed data from Eli Lilly & Co. from the first half of 2007 and found that only 25 percent of 161 organizations disclosed funding from the drug giant on their
Ortho Evra Sales Limericks and Other Pharma Gimmicks
Pharmaceutical companies use cheesy marketing gimmicks to help train their sales people. Rhymes and limericks are perennial favorites.
Someone sent me a few of the ones used for Ortho Evra. Get a load of these:
The patch contains hormones you knew;
EE and NGMN are impregnated in glue.
It blocks eggs from a poppin;
Dr. Elliott On Pharmaceutical Propaganda
I’ve had the opportunity to email Dr. Elliott several times since interviewing him and he’s just an all-around good guy. That sentiment was amplified today when I saw this column on CNN:
(CNN) — If you want to understand the way prescription drugs are marketed today, have a look at the 1928 book, "Propaganda," by
FDA may step up criminal prosecutions for off-label marketing
This is promising:
Drugmaker executives whose companies promote unauthorized uses of their medicines may be targeted by U.S. regulators for misdemeanor prosecutions, Food and Drug Administration Deputy Chief for Litigation Eric Blumberg said.
* * * *
‘“It’s clear we’re not getting the job done with large, monetary settlements,” Blumberg said. “Unless the government shows
Pfizer and Wyeth in trouble again for off-label marketing…
As I’ve mentioned before, the game plan for most pharmaceutical companies these days seems to be to (a) get a drug approved for a limited indication, and then (b) promote it as a cure for every ailment known to man. I thought the figures below were interesting:
The Justice Department on Tuesday joined a whistle-blower
Allergan’s $600 Million Dollar Headache
Drug marketing 101: The FDA approves drugs for specific ailments. Drug companies may not market the drug to treat any other type of ailment. If they do, it’s called off-label marketing and it is illegal.
Drug marketing 201: It’s often very profitable to engage in off-label marketing, because the fines you pay are less than…
Patients Are Concerned About Doctors & Pharmaceuticals
A little skepticism is a healthy thing:
Many patients taking prescription drugs believe that pharmaceutical companies have too much influence over their physicians’ prescribing practices, according to a new survey.
* * * *
About half of the medication users believed that their doctors were too eager to write a prescription when other non-pharmacological options
Rituxan Lawsuit Filed On Behalf Of Quadriplegic
Some people don’t understand why pharmaceutical companies shouldn’t be allowed to engage in off-label marketing. Here’s one reason:
Peetz was diagnosed with the autoimmune disorder thrombotic thrombocytopenia purpura in 1995, at age 11. According to the lawsuit, by 2003 Genentech and Biogen Idec were marketing Rituxan as an off-label treatment for Peetz’ condition, meaning the
GlaxoSmithKline Sales Rep Bonuses Are Tied To Values, Not Sales
I’ll be honest with you. I don’t trust pharmaceutical sales reps. Few of them are medical doctors, but they tell doctors which drugs should be prescribed for which patients. Traditionally, their compensation is based in part upon how many drugs the doctors they visit prescribe. This leads to a gigantic incentive to engage in off-label…